Insights and events
Cullen Taylor helps life sciences companies structure and negotiate their most complex agreements, particularly those involving the development, acquisition, and commercialization of intellectual property and technology. Cullen takes a practical, results-oriented approach to transactions, drawing on his broad experience to anticipate and address problems before they arise.
Cullen understands the legal and commercial risks that arise as parties enter, live under, and exit long-term partnering arrangements. Cullen is skilled at structuring and drafting contracts that address these concerns while keeping the client's business goals at front and center.
Cullen handles a variety of transactions within the life sciences industry, including product acquisition, licensing, research and development, collaboration, co-promotion, supply, and distribution agreements. His clients include pharmaceutical and biotechnology companies and device and diagnostics manufacturers with products and therapies at all stages of development. Cullen is often called upon to advise such clients on discovering, developing, and acquiring cutting-edge therapies and innovative technologies.
Cullen is head of the firm's Life Sciences Licensing and Commercial Transactions team. He regularly collaborates with his colleagues in the firm's Corporate and Regulatory practices to address intellectual property and technology-related issues that arise in corporate transactions and in the product approval process, and has advised a number of clients on licensing matters in relation to the recently implemented Inflation Reduction Act.
Cullen was recognized by Managing IP as the 2021 IP Transactional Lawyer of the Year for the Americas.
Representing Gilead Sciences in its collaboration with Dragonfly Therapeutics to develop and commercialize natural killer cell engagers in oncology and inflammation.
Representing Daiichi Sankyo in its collaboration with AstraZeneca to develop and commercialize Daiichi Sankyo's DS-1062, a potential treatment for multiple tumor types.
Represented Modex Therapeutics in its license and research collaboration with a multinational pharmaceutical company for the development of MDX-2201, Modex’s preclinical nanoparticle vaccine candidate targeting Epstein-Barr virus.
Representing BMS on its in-license from Rockefeller University of monoclonal antibodies for the treatment of COVID-19
Representing Gilead Sciences and Kite Pharma in a collaboration and license arrangement with oNKo-Innate to develop next-generation drug and engineered cell therapies focused on natural killer cells.
Representing Gilead Sciences in its collaboration with Yuhan Corporation to co-develop novel therapeutics for patients with advanced fibrosis due to NASH.
Representing Incyte Corporation in its license and collaboration agreement with MacroGenics relating to an anti-PD-1 antibody.
Representing multiple pharmaceutical companies and diagnostics manufacturers in collaboration agreements to develop companion diagnostics for drug products.
Representing Regeneron in a genomics collaboration with Geisinger Health Systems.
Representing Helsinn Healthcare in connection with license and collaboration agreements with MEI Pharma and Taiho Pharmaceuticals.
Representing Cormedix in various license, collaboration, supply, and distribution agreements relating to its Neutrolin product.
Representing Daiichi Sankyo in its co-commercialization agreement with AstraZeneca relating to MOVANTIK in the United States.
Representing Novartis in the sale of its animal health business to Eli Lilly for approximately US$5.4bn.
- J.D., Harvard Law School, 2000
- B.A., University of Virginia, with distinction, Phi Beta Kappa, 1997
- Member, American Bar Association
- Member, Virginia Bar Association